GHRH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-01-12 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
==== Offenders of unsound mind ==== Persons proven to be of unsound mind when they commit capital crimes, once found guilty, are not to be given the death penalty. These offenders can be sentenced to another form of indefinite detention under TPP, being detained at medical facilities, prisons or at some other safe places in custody, and subject to psychiatric review of their mental conditions until suitable for release.
Phase 0 and phase I drug trials seek healthy volunteers. Most other clinical trials seek patients who have a specific disease or medical condition. The diversity observed in society should be reflected in clinical trials through the appropriate inclusion of ethnic minority populations. Patient recruitment or participant recruitment plays a significant role in the activities and responsibilities of sites conducting clinical trials. All volunteers being considered for a trial are required to undertake a medical screening. Requirements differ according to the trial needs, but typically volunteers would be screened in a medical laboratory for:
Triple-decker complexes are composed of three Cp anions and two metal cations in alternating order. The first triple-decker sandwich complex, [Ni2Cp3]+, was reported in 1972. Many examples have been reported subsequently, often with boron-containing rings.
Sources: en.wikipedia.org
Increasing temperature, which evens out the Boltzmann population of states. Conversely, low temperature NMR can sometimes yield better results than room-temperature NMR, providing the sample remains liquid. Saturation of the sample with energy applied at the resonant radiofrequency. This manifests in both CW and pulsed NMR; in the first case (CW) this happens by using too much continuous power that keeps the upper spin levels completely populated; in the second case (pulsed), each pulse (that is at least a 90° pulse) leaves the sample saturated, and four to five times the (longitudinal) relaxation time (5T1) must pass before the next pulse or pulse sequence can be applied. For single pulse experiments, shorter RF pulses that tip the magnetization by less than 90° can be used, which loses some intensity of the signal, but allows for shorter recycle delays. The optimum there is called an Ernst angle, after the Nobel laureate. Especially in solid state NMR, or in samples containing very few nuclei with spin (diamond with the natural 1% of carbon-13 is especially troublesome here) the longitudinal relaxation times can be on the range of hours, while for proton-NMR they are often in the range of one second. Non-magnetic effects, such as electric-quadrupole coupling of spin-1 and spin-3/2 nuclei with their local environment, which broaden and weaken absorption peaks. 14N, an abundant spin-1 nucleus, is difficult to study for this reason. High-resolution NMR instead probes molecules using the rarer 15N isotope, which has spin-1/2.
=== Distribution === Following absorption, 2,6-DCBQ distributes predominantly to highly perfused organs, such as the liver and the kidneys. Its moderate lipophilicity facilitates the crossing of cellular membranes. The quinone structure allows for redox cycling between quinone and hydroquinone within tissues. This process can lead to the formation of reactive oxygen species (ROS), contributing to intracellular oxidative stress. Due to its high reactivity and its metabolic transformation, 2,6-DCBQ does not significantly accumulate in adipose tissue.
=== Guest === Christian Kane as Jacob Stone, one of the Librarians from the Portland, Oregon Annex who specializes in archaeology, art history, and architecture. He was introduced in The Librarians. Arielle Dombasle as Dame Anna Mirinoff (season 1) Celyn Jones as Cupid, God of Love; Vikram's friend (season 1) Ike Bennett as Pedro Worth, a friend of Connor Green (season 1) Hannah Devlin as Hermione Palvis, a descendant of the ancient Greek Muses who can make art come alive (season 1) Philip Rosch as Sir Lancelot du Lac (season 1), Elaine's former lover and fellow ex-knight of Camelot, who became immortal along with her when they summoned the power of his shield during a battle in Medieval times. Matt Frewer played Lancelot living as a 21st-century man and using the name "Dulaque" in The Librarians, serving as the main antagonist of the first season, with Jerry O'Connell playing his younger self.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.